Cargando…

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

BACKGROUND: Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase 2 GALAHAD trial (NCT02854436) demonstrated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Matthew R, Sandhu, Shahneen, George, Daniel J, Chi, Kim Nguyen, Saad, Fred, Thiery-Vuillemin, Antoine, Stàhl, Olaf, Olmos, David, Danila, Daniel C, Gafanov, Rustem, Castro, Elena, Moon, Helen, Joshua, Anthony M, Mason, Gary E, Espina, Byron M, Liu, Yan, Lopez-Gitlitz, Angela, Francis, Peter, Bevans, Katherine B, Fizazi, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387937/ https://www.ncbi.nlm.nih.gov/pubmed/37404070 http://dx.doi.org/10.18553/jmcp.2023.29.7.758

Ejemplares similares

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
por: Saad, Fred, et al.
Publicado: (2021)

Galahad: a web server for drug effect analysis from gene expression
por: Laenen, Griet, et al.
Publicado: (2015)

GALAHAD a library of thread-safe Fortran 90 packages for large-scale nonlinear optimization
por: Gould, N I M, et al.
Publicado: (2002)

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
por: Chi, Kim N, et al.
Publicado: (2023)

Examining the interactions of Galahad™ compound with viruses to develop a novel inactivated influenza A virus vaccine
por: Barnard, Dale L., et al.
Publicado: (2022)

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer
por: Thiery-Vuillemin, A., et al.
Publicado: (2021)

Niraparib for ovarian cancer
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
por: Uemura, Hiroji, et al.
Publicado: (2020)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
por: A’Hern, Roger, et al.
Publicado: (2011)

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
por: Carr, T. Hedley, et al.
Publicado: (2021)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study
por: CAUBET, MATTHIEU, et al.
Publicado: (2015)

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
por: Morosi, Lavinia, et al.
Publicado: (2020)

How to start niraparib in real-world Asian ovarian cancer patients?
por: Hong, Sook-Hee
Publicado: (2021)

Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress
por: Bezrookove, Vladimir, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Niraparib-induced STAT3 inhibition increases its antitumor effects
por: Zhao, Qianqian, et al.
Publicado: (2022)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial
por: Finelli, Antonio, et al.
Publicado: (2021)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel
por: Armstrong, Andrew J., et al.
Publicado: (2017)

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

Pancytopenia in a patient treated with fusidic acid and niraparib: a case report
por: Damerval, Margaux, et al.
Publicado: (2023)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
por: Thiery‐Vuillemin, Antoine, et al.
Publicado: (2021)

An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
por: Akay, Melek, et al.
Publicado: (2021)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
por: Lozano, Rebeca, et al.
Publicado: (2021)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iqmh6klgbsnjbfpiohmscaa87v